Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
REPLIGEN CORP
Bear Case (25th pct.)
-89.7% vs price
Base Case (Median)
-86.0% vs price
Bull Case (75th pct.)
-85.4% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $25.86 | -85.8% | High (40%) |
| PE Comparable | $16.62 | -90.9% | Medium (25%) |
| Graham Number | $24.93 | -86.3% | Medium (40%) |
| EV/EBITDA | $26.63 | -85.3% | Medium (20%) |
| EV/FCF | $37.49 | -79.4% | Medium (20%) |
| Earnings Power Value | $1.47 | -99.2% | Medium (50%) |
Based on 6 out of 7 methods, RGEN appears overvalued at the current price of $181.70. The base case fair value of $25.40 implies 86.0% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.